Literature DB >> 8749628

Alterations in gastric acidity in patients infected with human immunodeficiency virus.

L S Welage1, P L Carver, S Revankar, C Pierson, C A Kauffman.   

Abstract

In a randomized crossover trial, gastric acidity and gastric microbial colonization in 19 men infected with human immunodeficiency virus (HIV) (of whom nine had AIDS) were assessed. Gastric acidity was assessed during a baseline period and following pentagastrin or glutamic acid administration. Only two (22.2%) of the nine patients with AIDS and none of the non-AIDS patients were hypochlorhydric, as determined by maximal acid output. However, 60% and 67% of patients in the HIV-infected and AIDS groups, respectively, had persistently elevated gastric pH values during the baseline period. Both pentagastrin and glutamic acid significantly increased gastric acidity. Gastric colonization with Candida albicans and gram-positive mouth flora was common. Overall, this study demonstrates that many HIV-infected patients have elevated gastric pH values that may lead to alteration in drug absorption. The large degree of intrasubject and intersubject variability observed in gastric pH suggests that, unfortunately, one cannot predict which patients will have elevated gastric pH values.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8749628     DOI: 10.1093/clinids/21.6.1431

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  28 in total

1.  Cocrystals Mitigate Negative Effects of High pH on Solubility and Dissolution of a Basic Drug.

Authors:  Yitian M Chen; Naír Rodríguez-Hornedo
Journal:  Cryst Growth Des       Date:  2018-02-14       Impact factor: 4.076

Review 2.  Management of gastrointestinal disorders in children with HIV infection.

Authors:  Alfredo Guarino; Eugenia Bruzzese; Giulio De Marco; Vittoria Buccigrossi
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

3.  Gastric mucosal hyperplasia via upregulation of gastrin induced by persistent activation of gastric innate immunity in major histocompatibility complex class II deficient mice.

Authors:  T Fukui; A Nishio; K Okazaki; N Uza; S Ueno; M Kido; S Inoue; H Kitamura; K Kiriya; S Ohashi; M Asada; H Tamaki; M Matsuura; K Kawasaki; K Suzuki; K Uchida; H Fukui; H Nakase; N Watanabe; T Chiba
Journal:  Gut       Date:  2005-12-01       Impact factor: 23.059

4.  Food Safety Knowledge, Beliefs and Behavior of Persons with AIDS: A Multicenter Study.

Authors:  Mark S Dworkin; Caryn E Peterson; Weihua Gao; Angel Mayor; Robert Hunter; Edna Negron; Alison Fleury; C Lynn Besch
Journal:  Food Prot Trends       Date:  2013-01-01

5.  No relationship between gastric pH, small bowel bacterial colonisation, and diarrhoea in HIV-1 infected patients.

Authors:  C M Wilcox; K B Waites; P D Smith
Journal:  Gut       Date:  1999-01       Impact factor: 23.059

Review 6.  Delavirdine: a review of its use in HIV infection.

Authors:  L J Scott; C M Perry
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

7.  Atazanavir/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults.

Authors:  Chad J Achenbach; Kristin M Darin; Robert L Murphy; Christine Katlama
Journal:  Future Virol       Date:  2011-02       Impact factor: 1.831

8.  Pharmacokinetics of itraconazole (oral solution) in two groups of human immunodeficiency virus-infected adults with oral candidiasis.

Authors:  J Reynes; C Bazin; F Ajana; A Datry; J P Le Moing; E Chwetzoff; J C Levron
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

9.  HIV/AIDS patients display lower relative bioavailability of efavirenz than healthy subjects.

Authors:  Jackson K Mukonzo; Sarah Nanzigu; Dinko Rekić; Paul Waako; Daniel Röshammar; Michael Ashton; Jasper Ogwal-Okeng; Lars L Gustafsson; Eleni Aklillu
Journal:  Clin Pharmacokinet       Date:  2011-08       Impact factor: 6.447

10.  Clinical implications of the nelfinavir-proton pump inhibitor drug interaction in patients with human immunodeficiency virus.

Authors:  Parya Saberi; Dilrini K Ranatunga; Charles P Quesenberry; Michael J Silverberg
Journal:  Pharmacotherapy       Date:  2011-03       Impact factor: 4.705

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.